Fluocinolone Intraocular and Tofacitinib Citrate

• Generic Name: fluocinolone ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Iluvien, Retisert, Yutiq

Fluocinolone acetonide intravitreal implant is used in diabetic patients who have diabetic macular edema (DME). Macular edema is swelling in the back of the eye and may cause vision loss. Fluocinolone is used in patients who already have received steroid medicines and did not have an increase in intraocular pressure.

Fluocinolone acetonide intravitreal implant is also used to treat chronic non-infectious uveitis (redness, pain, or swelling of the eye that is not caused by infection) of the back part of the eye.

Fluocinolone is to be given only by or under the direct supervision of your doctor.

• Generic Name: tofacitinib
• Dosage Forms: n.a.
• Other Brand Names: Xeljanz, Xeljanz XR

Management of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate; can be used alone or in combination with methotrexate or other nonbiologic DMARDs (e.g., hydroxychloroquine, leflunomide, minocycline, sulfasalazine).

Concomitant use with biologic DMARDs, such as tumor necrosis factor (TNF) blocking agents (e.g., adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), interleukin-1 (IL-1) receptor antagonists (e.g., anakinra), anti-CD20 monoclonal antibodies (e.g., rituximab), selective costimulation modulators (e.g., abatacept), and anti-interleukin-6-receptor monoclonal antibodies (e.g., sarilumab, tocilizumab), not recommended.

Concomitant use with potent immunosuppressive agents (e.g., azathioprine, cyclosporine) also not recommended.

Management of active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.

Concomitant use with biologic DMARDs (see Rheumatoid Arthritis in Adults under Uses) or potent immunosuppressive agents (e.g., azathioprine, cyclosporine) not recommended.

Management of moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to TNF blocking agents.

Concomitant use with biologic therapies for ulcerative colitis or potent immunosuppressive agents (e.g., azathioprine, cyclosporine) not recommended.